In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for its commitment to advancing dermatological care, presented key findings from the DELTA 3 trial at the prestigious 82nd American Academy of Dermatology (AAD) Congress in San Diego, California. This marks the first public disclosure of the results […]
LEO Pharma A/S said that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for delgocitinib cream. Touted as a groundbreaking topical pan-Janus kinase (JAK) inhibitor, this cream is specifically designed for adult patients battling moderate to severe chronic hand eczema (CHE). This validation kicks off the official review process by the […]
Glenmark Pharmaceuticals Ltd., a global leader in pharmaceutical research, has secured the final nod from the U.S. Food & Drug Administration (U.S. FDA) for its Tacrolimus Ointment, 0.03%. This ointment stands as the generic counterpart to Leo Pharma AS’s Protopic Ointment, 0.03%. Marking its entry into the U.S. market, the product will be distributed by […]
Glenmark Pharmaceuticals has secured tentative approval from the US Food and Drug Administration (FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%. The product is the generic version of Enstilar Foam, 0.005%|0.064%, a psoriasis medication from Leo Pharma. For the 12-month period ending March 2022, the Enstilar Foam, 0.005%|0.064% market achieved annual sales of around $115.2 […]
LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant deal valued at approximately KRW 450 billion ($402 million). This licensing agreement, however, excludes South Korea, where JWP will retain exclusive rights. Under the terms of the agreement, LEO Pharma […]